Subject Index 2003

Africa
    history of leprosy, 106
    see also Malawi; Mozambique; Nigeria
Agranulocytosis, dapsone-induced, 167
Anetoderma, 275
Azathioprine, 171

Ballpen test, 42, 300
Bangladesh
    Acute Nerve Damage Study, 349
    socio-economic rehabilitation, 120
Begging, 281
Bell’s phenomenon, 383
Blisters packs, 259
Brazil
    delayed diagnosis in, 249
    impairment in, 337
Charcot deformity, 84
China
    history of leprosy, 107
    leprosy villages and leprosaria, 222
    socio-economic rehabilitation, 215
‘Client satisfaction’, 112
Clinical trials
    TRIPOD, 319
    TRIPOD 2, 300
    TRIPOD 3, 311
Clofazimine, 386
Corticosteroids, 87, 171
    blister packs, 259
    nerve function impairment, 319
    TRIPOD 3, 311
Dapsone, 167
Decision analysis, 240
Dehabilitation, 281
Delay in presentation, 349
Dexamethasone, 171
Diagnosis, 18
    delayed, 79, 249, 282
    serology in, 199
Disability, 120
    Brazil, 337
    People’s Republic of China, 215
    WHO disability grading, 366
    see also Prevention of disability

Education, 249
Electrophysiology, 374

ELISA test, 263
Epidemiology, 7, 31
    molecular, 11
Erythema nodosum leprosum, 171, 206
    treatment, 386
Excision arthroplasty, 63
Facial palsy, 383
Foot, neuropathic, 84, 86
Genetics, 11
Global Project for the History of Leprosy, 103
Guidelines for quality of leprosy services, 112
Guyana, knowledge and attitudes towards leprosy, 154
Healthcare workers, knowledge and attitudes towards leprosy, 154
Human immunodeficiency virus, 275
Immigrants, leprosy screening in, 240
Immune response, 206
Immunohistochemistry, 263
India
    dapsone-induced agranulocytosis, 167
    epidemiology, 31
    history of leprosy, 107
    leprosy control campaigns, 148
    International Leprosy Congress 2002, 7
Lepromin test, 21, 263
Leprosaria, 222
Leprosy elimination campaigns
    Brazil, 337
    India, 148
    Mozambique, 229
    Nigeria, 68
    leprosy villages, 222
Malawi, recurrence risk ratio, 133
Male/female sex ratio in leprosy, 180
Median nerve impairment, 374
Metatarsophalangeal joints, 63
Mitsuda reaction, 263
Molecular biology in diagnosis, 18
Molecular epidemiology, 11
Monitoring, serology in, 200
Mozambique, leprosy elimination campaigns, 229
Multibacillary leprosy, 2, 141
Multidrug therapy, 2, 141, 279
    and nerve function impairment, 35
Mycobacterium leprae, detection of, 18
Nepal, non-governmental organizations, 163
Nerve function impairment, 35, 126
  Brazil, 337
corticosteroids, 311, 319
  and delay in presentation, 349
  following prednisolone discontinuation, 328
median nerve, 374
sensory testing, 300
treatment, 87
ulnar nerve, 53, 374
unexplained, 357
Nerve trunk decompression, 374
Neuropathic foot, 84, 86
New case detection, 177
NFI see Nerve function impairment
NGOs see Non-governmental organizations
Nigeria, 279
delayed diagnosis, 79, 281
  field treatment of leprosy reactions, 259
  leprosy control, 68
Non-governmental organizations, 163

Obituaries
  Jo Colston, 100
  Paul W Brand, 294

Paucibacillary leprosy, 2
  ulnar and median nerves in, 374
Plantar ulcers, excision arthroplasty, 63
POD see Prevention of disability
Polymerase chain reaction, 18
Prednisolone, 259
  NFI following discontinuation, 328
Prevalence rates, 177
Prevention of disability (POD), 9
Primary neuritic leprosy, 88
Prognosis, 300
Prophylaxis, 319

Quality of leprosy services, 112
Recurrence risk ratio, 133
Rehabilitation see Socio-economic rehabilitation
Relapse, 200
Research, 8
Reversal reaction, 87, 206, 328

Screening
  in immigrants, 240
  serology in, 200, 201
Siegmess-Weinstein monofilament test, 42, 300
Sensory testing, 42, 300
Serology, 196, 263
Slit-skin smears, 21
Socio-economic rehabilitation, 9, 83, 120
  classification by objectives, 175
  People’s Republic of China, 215
  selection for, 129
Stigmatization, 120
Surgery
  excision arthroplasty, 63
tendon transfer, 53
Tendon transfer surgery, 53
Thalidomide, 206, 286, 288, 290, 294
Therapeutics, 8
TRIPOD 2, 300
TRIPOD 3, 311
Ulnar nerve impairment, 53, 374
WHO disability grading, 366
WHO Technical Advisory Group, 2
World Health Organization (WHO), 288